Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $66.90 and last traded at $65.00, with a volume of 255858 shares changing hands. The stock had previously closed at $66.18.
Gemini Therapeutics Price Performance
The firm has a market capitalization of $2.75 billion, a PE ratio of -63.50 and a beta of -0.12. The company has a fifty day moving average of $58.16 and a 200-day moving average of $50.13.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Micron Stock Under $100: Seize the AI-Driven Upside
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- Technology Stocks Explained: Here’s What to Know About Tech
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-usd-0005-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}